Rituximab biosimilar - Bio Sidus S.A.

Drug Profile

Rituximab biosimilar - Bio Sidus S.A.

Latest Information Update: 16 Aug 2013

Price : $50

At a glance

  • Originator Bio Sidus S.A.
  • Developer Biosidus S.A.
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Immunological disorders; Non-Hodgkin's lymphoma; Transplant rejection

Most Recent Events

  • 15 Aug 2013 Investigation in Immunological disorders in Argentina (Parenteral)
  • 15 Aug 2013 Investigation in Transplant rejection (prevention) in Argentina (Parenteral)
  • 15 Aug 2013 Investigation in Non-Hodgkin's lymphoma in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top